{"name":"Ankyra Therapeutics, Inc","slug":"ankyra-therapeutics-inc","ticker":"","exchange":"","domain":"ankyra.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxNUFc3RE11VDBhX2NEMWtyMmlmSi1Ha3lyQWh4dWpQN0w4RUFaMG9yamp0Rk56c3Y5NU1CQmFXN25GT2dWeUNTUDhQZG1oWU9qVWpCT0lmNjFfYktWLWZrMVpMLU9IMmc4aWZFSnhwUDJsbFREWldQUlpaTnlfb3JPaHZrdmRjU0VBMmR3M3FpMVRtdTNCMDNvUllDNmhiRUx1eTI2RFpJRDFvRFhiZHNjNUZrbFMtSXZKR3RONzZpRXZ6TGJHMkhzTGZIbUt4TjFBQ0oxdW84TTlBeG9Jc21ablF2dlRMYTZtRi04MTRXc0RWNEg2a0ZMTGRWNm9DYnVtaGhrb3VGN195OUNWYnhzNGMxMnhGZUJpcVpwb0Z3?oc=5","date":"2026-02-18","type":"trial","source":"Business Wire","summary":"Ankyra Therapeutics Presents First Preclinical Data on ANK-203, a Novel CD137-Anchored Immunotherapy Candidate, in Oral Session at AACR IO - Business Wire","headline":"Ankyra Therapeutics Presents First Preclinical Data on ANK-203, a Novel CD137-Anchored Immunotherapy Candidate, in Oral ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOQmhkQlJQRzJzbGVrREo5Vnh4MW9FbTBRSGF0VWp3N2ptTktmaFBxQXZVemdGSHVSc3Y3R2ZnY0U1clpmY1pTN0I5R0d6bXpjb0pnOHZWMF9KS0NoemZud0otYVZQOFRnNHF6dW15c3R5ZDNkcWo3RlZJTFVCNDg5MGl6ZDIzcGhxM1ZkNVln?oc=5","date":"2025-12-19","type":"pipeline","source":"Fierce Biotech","summary":"Pfizer RNA leader runs to Replicate—Chutes & Ladders - Fierce Biotech","headline":"Pfizer RNA leader runs to Replicate—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNMDR1MGtsTWYzZ2cxaGN4WWRoQnhia285b29sajFzbmhrWm8xQXRKblZRc01weS1vc2R1azhaWjdiM0g4NUw1M0lHREtMV1l0dXFNaEF5WDl2ZHByTVlzbzMyWm5TQWtrMUhVZHRlWnBnNl9qdXJMWWllOXhSSjhTejZnT1FPQnh4ZHd2azlZaUFmdkN5X1d5eUJxckpVWGltdVF0VkI3dUtHOGJnejBNU2VhS0ZrbzQwamEya3Q5OGJYQQ?oc=5","date":"2025-12-15","type":"pipeline","source":"Business Wire","summary":"Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO) - Business Wire","headline":"Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNT0RDdEdiUC1wR213VFBwQXotR2w5LXE3TWxyeUF5TnhiM09sZ0VkOGlkMElqNDZiRkY4cjJ4TXY3cEZ2ZGthMDd6b0l1dE1lMjkwekpzYmVnYlVTaG44VWw4enZBTTFhbGdqY1FVU1VfWXF6Y0ZKOGJoOF9GVWw1SWFtVQ?oc=5","date":"2025-05-27","type":"pipeline","source":"Labiotech.eu","summary":"9 biotechs making waves in interleukin therapeutics in 2025 - Labiotech.eu","headline":"9 biotechs making waves in interleukin therapeutics in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQZnd4ay1XQ1hyY2taMzBuSEpLaDlRRXVac1ZKTlNLbFFJVjdUbG16THVBMm5SMWtaTkxaVVJNaTdVZzBPb25OcmFwZlpIcU1URUh3dUdzRF9nakcyMmFDSHlIZ3FXNzVEbTNucFMzOFEtaWdWZ09rOTgyWkp6V1NGeGdfbDhrS2FEN0JwOVlTc3J6VG1lQmI3TGtMMUloWXc?oc=5","date":"2025-02-28","type":"pipeline","source":"Fierce Biotech","summary":"Private equity firms take over bluebird's nest—Chutes & Ladders - Fierce Biotech","headline":"Private equity firms take over bluebird's nest—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQd0xlQmJ2cTlGeG5aM215QmZtQzJuY2VlSlBiRDFoeGpWcFhPWThSN0dibkhfaXlyajdFTlR1MW1ZLUFrZ3NvY20wbk1Oc01XRkhBMjM4VHlkWXd6aElSanNLS0llSndHQ2dScF96NnEtYmZjcW43U2hiSGxndHJJREZYeWwwN0h4ZTBHaldKY2M?oc=5","date":"2023-08-07","type":"pipeline","source":"BioCentury","summary":"Khoo Shih named CEO of Singapore’s ClavystBio - BioCentury","headline":"Khoo Shih named CEO of Singapore’s ClavystBio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNTjZkYTlrTWstNDBxbjlEeUpLaGdJMkpZUk9ON1B2Q3d4TmZkNG50aE5PQlA2d2FaXzd6dUkwbnY0bWlkeFd5c2JaQ3pwRVZkUmFTejJiZjBaUzhLc2ZLenJFeGQ0eTQ0Yy03RUEwM05oZFdFODZxU19pWE0zRXo3ZzluUmJMT3llT2RfNzhjOElCY0s4?oc=5","date":"2022-10-21","type":"deal","source":"Fierce Biotech","summary":"Chutes & Ladders—Ayala sheds execs amid Advaxis merger - Fierce Biotech","headline":"Chutes & Ladders—Ayala sheds execs amid Advaxis merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNMTFZNDNieG5YUVdqMEVBTEdhZTBVUXp3TWhtUU4zalc1VFJDbkRkQllEdkRRUkx5aEpaY016ZlJjMEI4bVlXWmxmVE1SZkxhanRNS2pnTHZxQ3djMkhqd0NTdVZGX29BMl9EYnRTU01sZjMtWTRMZWc5ZHVDeHZ3X2FYOHRKVTUwaHZyTExGYWI2ZUxJWDdaNzNpbXYyQVkwMm0wS0YzcGhzU3kwNnlNWXRwZ181UEJhY0NHdVhmcHZzNVQzd1E?oc=5","date":"2021-11-12","type":"pipeline","source":"Fierce Biotech","summary":"Gerngross biotech Ankyra Therapeutics nabs $45M series B to jump into the clinic, hires new CMO - Fierce Biotech","headline":"Gerngross biotech Ankyra Therapeutics nabs $45M series B to jump into the clinic, hires new CMO","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}